⌘K
Loading ticker…
Jasper Therapeutics, Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, Jasper Therapeutics, Inc. Common Stock (JSPR) has a 3-month relative strength percentile of 3 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 24. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 19.1%, relative volume 1.81×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
3 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
JSPR is in a stage 4 downtrend, week 12. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -54.5% / -76.9%.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
JSPR is held by 2 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $730K notional.
Top 2 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $730K |
| VXFVanguard Extended Market ETF | 0.00% | $273K |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JSPR Jan avg: 52.64% median: 15.09% win: 50% σ: 141.86% n: 4 2022-04-12 → 2026-05-29 | JSPR Feb avg: 21.25% median: 5.69% win: 50% σ: 40.37% n: 4 2022-04-12 → 2026-05-29 | JSPR Mar avg: -8.01% median: -16.85% win: 25% σ: 33.30% n: 4 2022-04-12 → 2026-05-29 | JSPR Apr avg: -2.14% median: 0.00% win: 60% σ: 21.46% n: 5 2022-04-12 → 2026-05-29 | JSPR May avg: 3.60% median: 3.93% win: 80% σ: 10.39% n: 5 2022-04-12 → 2026-05-29 | JSPR Jun avg: -15.60% median: -12.08% win: 25% σ: 16.84% n: 4 2022-04-12 → 2026-05-29 (current) | JSPR Jul avg: -14.54% median: -10.31% win: 25% σ: 25.08% n: 4 2022-04-12 → 2026-05-29 | JSPR Aug avg: -0.89% median: -1.46% win: 50% σ: 14.98% n: 4 2022-04-12 → 2026-05-29 | JSPR Sep avg: -32.57% median: -29.04% win: 0% σ: 21.95% n: 4 2022-04-12 → 2026-05-29 | JSPR Oct avg: -1.20% median: -4.96% win: 25% σ: 9.30% n: 4 2022-04-12 → 2026-05-29 | JSPR Nov avg: -8.10% median: -10.40% win: 25% σ: 11.71% n: 4 2022-04-12 → 2026-05-29 | JSPR Dec avg: -0.40% median: -3.41% win: 25% σ: 21.40% n: 4 2022-04-12 → 2026-05-29 |